17 November 2026

London Life Sciences Week 2026 day two: delegations, patients and regulation

Chris Molloy, CEO of BIA, addressing attendees at the International Delegation Breakfast Networking event

Chris Molloy, CEO of BIA, addressing attendees at the International Delegation Breakfast Networking event

Isomorphic Labs raises $5 billion

London-headquartered Isomorphic Labs announced on Tuesday that it has closed a $5 billion Series C round, co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz joined as a new investor, Alphabet continued its backing, and every existing investor took part, including the UK Sovereign AI Fund. It comes six months after the company’s $2.1 billion Series B. BioSpace reports it as the industry’s largest private fundraise ever, ahead of the $3 billion Altos Labs raised in 2022. The company says the money will go on scaling its AI drug design engine and taking its drug candidates towards clinical trials.

Our chief executive, Chris Molloy, said:

Isomorphic Labs’ £3.8 billion ($5 billion) investment is not only a new peak for UK-founded companies; it is the largest ever venture capital raise for life sciences globally. This is a powerful vote of confidence in UK life sciences and a strong endorsement for our TechBio sector. Bringing breakthrough AI and drug discovery together offers extraordinary potential to tackle diseases that still lack effective treatments.

When companies with exceptional science receive exceptional backing, it enables them to grow, scale and serve the world from here. Britain can be a place where it is common for scientific breakthroughs to become global businesses and, ultimately, life-changing medicines.

In addition, read our six key messages for London Life Sciences Week.

An early start with international delegations

The morning began at Victoria House, where we welcomed the organisers of overseas delegations for the International Delegation Networking Breakfast. These are the people who bring teams, investors and companies to the UK and help UK companies find partners abroad. Our Chief Executive, Chris Molloy, told the room: “We hope that this morning, each of you from around the world, in this United Nations of life sciences, can meet one another, can enjoy one another’s company and learn something.”

Innovation reaching patients

At 180 Studios, the Frontiers of patient care programme, chaired by Hannah Witty of NHS England, looked at how innovation reaches the people who need it. Sessions covered transforming patient outcomes through data, with Our Future Health and Genomics England, and the role of the private sector in healthcare innovation.

Women's health had its own place on the agenda. Dr Thomas Bainton and Dr Philip Pratt discussed technology and the future of endometriosis care, and the programme went on to digital innovation and health inequalities in London, and to the future of cancer care with Professor Susana Banerjee and Professor Lars Erwig.

Wear pink Tuesday

BIA London Life Sciences Week Pink picture wear pink Tuesday

Wear pink Tuesday

At midday, female leaders and allies from across the week gathered at Lincoln’s Inn Fields in pink for a group photo. The picture celebrates diversity and inclusion in life sciences, and is a reminder of the role female leaders and allies play in the sector. It was organised by our Managing Director Jane Wall, Anne Horgan, Partner at Cambridge Innovation Capital, and Elisa Petris, Managing Partner at Syncona. Equal Productions took the photograph.

The BIA view: life sciences is built by its people. The sector draws on the same university base that produces the science, and keeping that pipeline full is the next job.

The second day of the MHRA summit

The DIA-MHRA Global Summit continued at Senate House, with our chief executive Chris Molloy on a panel. Chris McDonald announced a new Advance GxP programme to support innovative manufacturing. Coordinated by MHRA & OLS, he described it as “bigger than a new service – it is a new kind of regulatory culture”.

The BIA view: the UK's regulator has had a strong year, with every target timeline met in 2025 to 2026, and we want it to keep a strong voice in global standard-setting.

Cancer science from discovery to clinic

The Cancer Innovators Forum ran through the afternoon, opened by Chris McDonald MP, Minister for Science, Innovation and Investment. Tony Ng of GSK spoke on the future of cancer science, panels followed the route from discovery to the clinic, and the investment session asked where the money is for cancer innovation.

That evening, bioProcessUK began in Brighton with pre-conference drinks, ahead of the conference on Wednesday and Thursday.

Tomorrow: investors, early-stage founders and our International Investor Summit.